FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC
The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Related Articles
3 QUESTIONS ON . . . ‘Spillover’ Savings for the Oncology… : Oncology Times
An abstract is unavailable.
Evaluating clinical utility of comprehensive genomic profiling—challenges and opportunities
Practice of cancer precision medicine relies on availability of advanced molecular diagnostic tools to guide use of targeted therapies, which now comprise
‘We need a new language for talking about stage 4 cancer’ – Kate’s story
‘We need a new language for talking about stage 4 cancer’ – Kate’s story
Advancing ADC development through target expression insights
Kristien Borremans, PhD, KU Leuven, Louvain, Belgium, comments on how findings from assessing mRNA expression of antibody-drug conjugate (ADC) targets in normal and metastatic breast…
Atezolizumab Combo Results Shows Promising Option in EGFR-Mutated NSCLC
Atezolizumab combination therapy elicited better responses in patients with PD-L1 expression of 1% or more with EGFR-mutant NSCLC.
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
340B Program Does Not Increase Access to Targeted Therapy for Prostate Cancer
Researchers found that prostate cancer patients with greater socioeconomic disadvantages were less likely to receive targeted therapy, and participation in the 340B program did not…
How to treat older patients with follicular lymphoma in the first‑line setting
During the Lymphoma Hub Steering Committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on, How to treat older…
New Horizons in HSCT-TMA: Expert Perspectives and Pearls for Practice
This live educational event is intended for learners to be better able to understand the dynamic data evaluating diagnostic and care strategies for hematopoi…
Blood Pressure Fluctuations Linked to Cognitive Decline in Older Adults
A new study highlights the link between visit-to-visit blood pressure variability (BPV) and cognitive decline in older adults. Read on!
